Dynavax Technologies Stock Today
| DVAX Stock | USD 12.37 0.20 1.64% |
Performance3 of 100
| Odds Of DistressLess than 12
|
Dynavax Technologies is trading at 12.37 as of the 21st of November 2024; that is 1.64% increase since the beginning of the trading day. The stock's open price was 12.17. Dynavax Technologies has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Dynavax Technologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of May 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of February 2004 | Category Healthcare | Classification Health Care |
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 131.46 M outstanding shares of which 18.84 M shares are currently shorted by private and institutional investors with about 8.88 trading days to cover. More on Dynavax Technologies
Moving against Dynavax Stock
| 0.76 | PALI | Palisade Bio | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.7 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.69 | INZY | Inozyme Pharma | PairCorr |
| 0.62 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.57 | KTTA | Pasithea Therapeutics | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Dynavax Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business President | Riccardo Manetti | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDynavax Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dynavax Technologies' financial leverage. It provides some insight into what part of Dynavax Technologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dynavax Technologies (DVAX) is traded on NASDAQ Exchange in USA. It is located in 2100 Powell Street, EmeryVille, CA, United States, 94608 and employs 408 people. Dynavax Technologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.6 B. Dynavax Technologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 131.46 M outstanding shares of which 18.84 M shares are currently shorted by private and institutional investors with about 8.88 trading days to cover.
Dynavax Technologies currently holds about 518.17 M in cash with 100.56 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.1.
Check Dynavax Technologies Probability Of Bankruptcy
Ownership AllocationThe majority of Dynavax Technologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dynavax Technologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dynavax Technologies. Please pay attention to any change in the institutional holdings of Dynavax Technologies as this could imply that something significant has changed or is about to change at the company.
Check Dynavax Ownership Details
Dynavax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Eventide Asset Management, Llc | 2024-06-30 | 2.9 M | |
| Tang Capital Management Llc | 2024-06-30 | 2.5 M | |
| Great Point Partners Llc | 2024-06-30 | 2.4 M | |
| Blair William & Co | 2024-06-30 | 2.4 M | |
| Renaissance Technologies Corp | 2024-09-30 | 2.3 M | |
| Millennium Management Llc | 2024-06-30 | 1.6 M | |
| Mizuho Markets Americas Llc | 2024-09-30 | 1.4 M | |
| Fisher Asset Management, Llc | 2024-09-30 | 1.4 M | |
| Northern Trust Corp | 2024-09-30 | 1.3 M | |
| Blackrock Inc | 2024-06-30 | 21.9 M | |
| Deep Track Capital, Lp | 2024-09-30 | 12.5 M |
Dynavax Technologies Historical Income Statement
Dynavax Stock Against Markets
Dynavax Technologies Corporate Management
| David Novack | Sr. VP of Operations and Quality | Profile | |
| Eric Frings | Site VP | Profile | |
| Robert MD | Medical Development | Profile | |
| Donn Casale | Senior Officer | Profile | |
| Nicole Arndt | Sr Relations | Profile |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.